<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A prospective multicenter trial of 119 children 1 to 18 years of age with newly diagnosed <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) was conducted, comparing treatment using antithymocyte globulin (ATG), <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> (CyA), and <z:chebi fb="1" ids="4315">danazol</z:chebi> (DAN) with or without rhG-CSF (400 microg/m(2), day on days 1-90) </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> children with very severe AA received rhG-CSF (VSAA group, n = 50) </plain></SENT>
<SENT sid="2" pm="."><plain>The other children were randomized to receive ATG, CyA, DAN, and rhG-CSF (G-CSF+ group, n = 35) or ATG, CyA, and DAN without rhG-CSF (G-CSF- group, n = 34) </plain></SENT>
<SENT sid="3" pm="."><plain>After 6 months, the hematologic response rate was 71%, 55%, and 77% in the VSAA group, G-CSF+ group, and G-CSF- group, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>There was no difference in the incidence of febrile episodes and documented <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> between the G-CSF+ and G-CSF- groups </plain></SENT>
<SENT sid="5" pm="."><plain>Bone marrow transplantation (BMT) was attempted in 22 patients in whom initial immunosuppressive therapy (IST; n = 18) failed or in whom a relapse occurred after an initial response (n = 4) </plain></SENT>
<SENT sid="6" pm="."><plain>Nineteen of the 22 patients are alive and well after a median follow-up of 18 months (range, 3 to 66 months) since BMT </plain></SENT>
<SENT sid="7" pm="."><plain>The probability of survival at 4 years was 83% +/- 7% in the VSAA group, 91% +/- 5% in the G-CSF+ group, and 93% +/- 6% in the G-CSF- group </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>)/<z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) developed in one patient in each of the three groups; the overall risk for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was 3% +/- 2% at 4 years </plain></SENT>
<SENT sid="9" pm="."><plain>Because the results of IST were encouraging, it is suggested that children with AA receive IST as first-line therapy if there is no human leukocyte antigen-matched sibling donor </plain></SENT>
</text></document>